Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

January 2019

Pharmacy and Therapeutics Committee Meeting Update


At the Dec. 3, 2018 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed the medications below and decided the following:

P&T Committee Review and Decisions

Name

Indication

Decision

Calcitonin Gene Receptor Peptide – Class Review:

Aimovig (erenumab-aooe)

Emgality (galcanezumab-gnlm)

Ajovy (fremanezumab-vfrm)

Used for the preventive treatment of migraine in adults.

• Premium and Value formularies: Aimovig and Ajovy moved to preferred brand with prior authorization. Emgality moved to non-preferred brand with prior authorization.

• Medicare Advantage Formulary: Aimovig and Emgality moved to preferred brand with prior authorization. Ajovy moved to non-preferred brand with prior authorization.

Xofluza (baloxavir marboxil)

Used to treat the flu in patients 12 years of age and older who have been symptomatic for no more than 48 hours.

• Premium and value formularies: Moved to preferred brand

• Medicare Advantage formulary: Moved to preferred brand

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

HPHConnect for Providers Getting a New Look in 2019

2019 Quality Grant Applications Due by Feb. 15

HEDIS 2019 Coming Soon: Your Cooperation is Crucial

HPI to Administer BMC HealthNet Plan

Behavioral Health: Services for Improved Access

CLINICIAN CORNER

New Opioid Safety Edits for 2019 Medicare Advantage Plans

Medical Policy Update: Tumor Treating Fields

Reminder: Formulas and Enteral Nutrition Require Prior Authorization

Updates to Proton Beam Therapy Medical Policy

Lumoxiti Now Covered with Prior Authorization

TriVisc and Jivi Now Covered with Prior Authorization

Pharmacy and Therapeutics Committee Meeting Update

OFFICE ASSISTANT

Coding Program Launching in January for Medicare Advantage

PUBLICATION INFORMATION

Robert Farias,
Senior Vice President, Corporate Network Strategy

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator